Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Artrya Reports FY2026 Results as US Commercial Expansion Supports Growth Plans
Highlights:
Artrya Limited (ASX: AYA), a medical technology company developing artificial intelligence solutions for coronary artery disease assessment, presented its FY2026 financial results and operational update on 1 September 2026. The presentation highlighted progress in commercial deployment, customer adoption and product development as the company works to expand its presence in the US healthcare market.
Commercial Progress and Customer Expansion
During FY2026, Artrya secured three US healthcare customers: Tanner Health, Northeast Georgia Health System and Cone Health. These partnerships established the company's initial commercial foundation, supported by multi-year contracts and deployment activities.
Tanner Health became the first customer to integrate Salix® across five hospitals, with the platform supporting clinical workflows and generating revenue. The presentation also reported that cardiologists using the platform achieved 50–80% time savings in reporting, helping reduce after-hours and weekend workloads.
Northeast Georgia Health System went live clinically in July 2026, while Cone Health was progressing through integration. Artrya expects to expand usage across these healthcare networks and increase revenue as more scans are processed through its technology.
Financial Position and FY2026 Performance
Artrya reported AU$74.0 million in cash and no debt as of 30 June 2026. The company also secured AU$80.0 million in funding during FY2026 to support commercial expansion and product development.
Its statutory financial results showed revenue of AU$28,000 for FY2026, compared with AU$28,000 in FY2025. However, the company recorded a net loss after tax of AU$25.183 million, compared with AU$16.406 million a year earlier. Total expenses increased to AU$33.275 million, reflecting higher expenditure on consultants, employee benefits and other operating requirements.
The company attributed its investment to developing its Salix® product range, regulatory submissions and building the operational capacity required for expansion into the US market.
Salix® Platform and Regulatory Milestones
Artrya's Salix® platform analyses coronary CT angiography scans to provide insights into coronary anatomy and plaque characteristics. The company said its Coronary Anatomy and Coronary Plaque modules had received US Food and Drug Administration clearance, with commercial deployments underway.
Salix® Coronary Flow remained a key development priority, with FDA clearance targeted for the end of calendar year 2026. The company also launched the SAPPHIRE study across six major US healthcare systems to evaluate its plaque analysis technology and strengthen clinical validation.
Outlook for FY2027
Artrya plans to increase scan volumes, expand its customer base and convert additional SAPPHIRE participants into commercial customers. It also aims to complete further product and regulatory milestones while strengthening its US customer support operations.
Conclusion
Artrya's FY2026 update highlighted progress in commercial deployment alongside continued investment and operating losses. Its cash reserves provide funding for planned expansion, while future growth will depend on broader customer adoption, increased scan volumes and successful delivery of its regulatory and commercial objectives.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au